New scan could spot lung scarring early
NCT ID NCT03535545
First seen Mar 01, 2026 · Last updated May 11, 2026 · Updated 7 times
Summary
This early-phase study is testing a new imaging agent called [68Ga]CBP8 to see if it can safely detect collagen buildup (scarring) in the lungs of people with pulmonary fibrosis and lung cancer. Researchers will compare scans from healthy volunteers and patients to see if the agent can spot fibrosis and predict how the disease will progress. The study involves up to 100 participants and is currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.